Skip to Content

Portrazza (necitumumab) Disease Interactions

There are 5 disease interactions with Portrazza (necitumumab):


EGFR inhibitors (Includes Portrazza) ↔ CV/electrolyte imbalance

Severe Potential Hazard, Moderate plausibility. Applies to: Hypokalemia, Hypocalcemia, Heart Disease, Cardiovascular Disease, Electrolyte Abnormalities, Magnesium Imbalance

The use of certain EGFR inhibitors has been associated with progressive decreases in serum magnesium levels leading to severe cases of hypomagnesemia and accompanying electrolyte abnormalities, including hypocalcemia, and hypokalemia. The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of these agents. Periodically monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia, during and for at least 8 weeks following the completion of therapy. Caution is recommended when using these agents in patients predisposed to electrolyte imbalances and those with a history of coronary artery disease, congestive heart failure, or arrhythmias. Replete magnesium and other electrolytes as appropriate.


EGFR inhibitors (Includes Portrazza) ↔ dermatologic toxicities

Severe Potential Hazard, Moderate plausibility. Applies to: Dermatitis - Drug-Induced

Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors. Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae. It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications. Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.


EGFR inhibitors (Includes Portrazza) ↔ ocular disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Ocular Infection

Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis. It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.


Necitumumab (Includes Portrazza) ↔ thromboembolic disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Thrombotic/Thromboembolic Disorder

Venous and arterial thromboembolic events (VTE and ATE), some fatal, were observed with necitumumab in combination with gemcitabine and cisplatin. Caution is recommended when using necitumumab in patients with a reported history of VTE or ATE. Necitumumab should be discontinued in patients with serious or life threatening VTE or ATE.


Necitumumab (Includes Portrazza) ↔ renal/liver impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease, Renal Dysfunction

No formal studies have been conducted to evaluate the effect of renal and hepatic impairment on the exposure to necitumumab. Renal function and mild or moderate hepatic impairment has no influence on the exposure to necitumumab based on the population pharmacokinetic analysis. No data is available for patients with severe hepatic impairment. Cation and monitoring is recommended for these patients.

Portrazza (necitumumab) drug interactions

There are 4 drug interactions with Portrazza (necitumumab)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.